LXRX - NASDAQ

Lexicon Pharmaceuticals, Inc.

LXRX·NASDAQ

$1.85

-2.1%

HealthcareBiotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$821.76M

EPS-0.1400

P/E Ratio-13.21

Earnings Date07/30/2026

184.99M

Assets

-38%

3Y-5.0%

5Y-9.0%

10Y-61.0%

77.45M

Total Liabilities

-49%

3Y-

5Y+63.0%

10Y-76.0%

107.54M

Total Equity

-26%

3Y-8.0%

5Y-31.0%

10Y-32.0%

Lexicon Pharmaceuticals, Inc. Funding & Solvency Profile

LXRX · NASDAQ

Current Assets

Cash & Cash Equivalents34.33M

Net Receivables2.38M

Inventory281.00K

Other Current Assets3.00M

Total Current Assets102 M

Non-Current Assets

Property, Plant & Equipment9.18M

Goodwill & Intangible Assets44.54M

Long-Term Investments0.00

Other Non-Current Assets29.37M

Total Non-Current Assets39 M

Total Assets

184.99M

Financial Health Analysis

Current Ratio

4.88x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.72x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

81 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

55% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Lexicon Pharmaceuticals, Inc. Balance Sheet

LXRX • NASDAQ

Lexicon Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	34.3M	66.7M	22.5M	46.3M	64.1M	126.3M	36.1M	160.1M	310.8M	346.5M	521.4M	339.3M	129.1M	223.2M	186.3M	47.2M	100.6M	85.9M	22.9M	30.2M
Short-Term Investments	61.9M	171.3M	147.6M	92M	22.7M	26M	235.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	95.4M	163.9M	62M	17.2M	235.8M	49.8M
Cash & Short-Term Investments	96.2M	238M	170M	138.4M	86.7M	152.3M	271.7M	160.1M	310.8M	346.5M	521.4M	339.3M	129.1M	223.2M	281.7M	211.1M	162.5M	103.1M	258.8M	80M
Net Receivables	2.4M	3.5M	1M	28K	14K	395K	56.5M	5.9M	4.8M	7.5M	911K	1M	790K	1.4M	350K	744K	815K	568K	1.8M	1.2M
Accounts Receivables	2.4M	3.5M	1M	28K	14K	395K	56.5M	5.9M	4.8M	7.5M	911K	1M	790K	1.4M	350K	744K	815K	568K	1.8M	1.2M
Inventory	281K	231K	381K	0.0	0.0	0.0	4.2M	4.7M	1.9M	0.0	0.0	4.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	2.2M	5M	5.3M	2.7M	4.4M	3.9M	10.1M	4.8M	4.6M	6.3M	3.7M	2.9M	6.4M	5.5M	4.1M	4.4M
Other Current Assets	3M	4.5M	5.1M	2.5M	0.0	0.0	0.0	2.7M	4.4M	3.9M	10.1M	23.8M	4.6M	6.3M	0.0	0.0	0.0	0.0	0.0	4.4M
Total Current Assets	101.9M	246.2M	176.5M	140.9M	88.9M	157.7M	337.8M	173.3M	322M	357.9M	532.4M	369M	134.6M	230.9M	285.8M	214.7M	169.7M	109.2M	264.7M	85.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	9.2M	7.3M	7.5M	8.5M	3.4M	295K	14M	15.9M	17.7M	19.4M	21.2M	1.1M	41.4M	42.6M	46.4M	53.4M	58.8M	65.1M	70.8M	78.2M
Goodwill	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	25.8M	25.8M	25.8M	25.8M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	19.7M	50.1M	51.9M	53.4M	53.4M	53.4M	53.6M	53.6M	53.6M	53.6M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	44.5M	44.5M	44.5M	44.5M	44.5M	44.5M	64.3M	94.7M	96.4M	97.9M	97.9M	97.9M	98.1M	98.1M	98.1M	98.1M	25.8M	25.8M	25.8M	25.8M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5M	-4.9M	-468.4M	-413.6M	0.0	0.0	0.0	0.0	0.0	0.0	55.7M	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5M	4.9M	468.4M	413.6M	0.0	0.0	0.0	0.0	0.0	0.0	-55.7M	0.0	0.0
Other Non-Current Assets	29.4M	368K	828K	412K	0.0	1.2M	1.7M	285K	429K	461K	3.3M	3.4M	144K	109K	205K	619K	3.5M	61.5M	8M	724K
Total Non-Current Assets	83.1M	52.2M	52.9M	53.4M	48M	46.1M	80M	110.8M	114.5M	117.8M	122.4M	102.4M	139.6M	140.8M	144.7M	152.1M	88.1M	152.3M	104.6M	104.7M
Total Assets	185M	298.4M	229.4M	194.3M	136.9M	203.8M	417.7M	284.1M	436.5M	475.6M	654.8M	471.4M	274.2M	371.8M	430.5M	366.9M	257.8M	261.5M	369.3M	190.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.1M	14.8M	14.4M	10.4M	9.2M	5.5M	12.2M	12.1M	38.8M	52.9M	19.7M	13.1M	9.7M	7.7M	6M	3.2M	5.9M	7.9M	7.3M	6.5M
Accounts Payable	3.1M	14.8M	14.4M	10.4M	9.2M	5.5M	12.2M	12.1M	38.8M	52.9M	19.7M	13.1M	9.7M	7.7M	6M	3.2M	5.9M	7.9M	7.3M	6.5M
Accrued Expenses	0.0	14.6M	6.3M	7.8M	6.2M	22.9M	32M	21.2M	12.3M	32.1M	24.8M	10.1M	7.7M	8.9M	13.8M	6.3M	5.6M	6.6M	9.1M	7.3M
Short Term Debt	6.2M	0.0	0.0	0.0	0.0	11.6M	11M	1.1M	14.1M	16.3M	2M	20.2M	1.7M	1.6M	1.4M	1.1M	38.5M	963K	880K	816K
Capital Lease Obligations (Current)	0.0	1.2M	1.3M	1.3M	1.1M	553K	553K	-15.5M	-12M	-32.1M	-24.8M	-10.1M	-7.7M	-8.9M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4M	40.1M	63.4M	76.5M	1.6M	195K	128K	119K	214K	942K	5.7M	18M	31.3M
Other Current Liabilities	11.5M	14.7M	9.6M	3.7M	5.7M	6.2M	9.6M	-1.1M	252K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	20.9M	45.2M	31.5M	23.2M	22.1M	46.8M	65.3M	36.8M	124.1M	164.6M	123M	45M	19.3M	18.3M	21.4M	10.8M	51M	21.2M	35.3M	46M
NON-CURRENT LIABILITIES
Long Term Debt	49.4M	100.3M	99.5M	48.6M	0.0	0.0	234.2M	243.9M	231.6M	85.2M	101M	87.5M	20.2M	21.9M	23.5M	27.3M	28.5M	29.5M	30.5M	31.4M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27M	62.5M	112.3M	185.7M	14.3M	13.6M	14M	14.2M	14.2M	15.2M	14.2M	16.1M	26.7M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6M	6M	18.7M	18.7M	18.7M	18.7M	18.7M	18.7M	18.7M	-39.4M	-14.2M	-16.1M	-26.7M
Other Non-Current Liabilities	582K	0.0	0.0	0.0	0.0	0.0	0.0	238K	292K	805K	14.4M	23.5M	32.4M	32.3M	55.1M	48.8M	616K	764K	759K	739K
Total Non-Current Liabilities	56.6M	107.2M	104.8M	54M	1.2M	611K	235.3M	273.8M	260.3M	153.6M	246M	142.4M	84.7M	86.8M	111.6M	109.1M	43.3M	44.5M	47.4M	58.8M
Capital Lease Obligations	6.6M	8.1M	6.6M	6.7M	2.3M	1.2M	553K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	77.4M	152.5M	136.3M	77.2M	23.3M	47.4M	300.6M	310.5M	384.4M	318.2M	369M	187.4M	104M	105.1M	132.9M	119.9M	94.3M	65.7M	82.7M	104.8M
SHAREHOLDERS' EQUITY
Treasury Stock	-5.2M	-4.6M	-2.9M	-2.1M	-7.5M	-4.8M	-3.8M	-2.9M	-1.9M	-3.4M	-2.7M	-2.4M	-1.5M	-630K	-345K	-237K	-88K	0.0	0.0	0.0
Common Stock	366K	363K	245K	189K	150K	142K	106K	106K	106K	105K	104K	726K	514K	512K	480K	338K	176K	137K	137K	78K
Additional Paid-In Capital	2.1B	2.1B	1.9B	1.7B	1.6B	1.6B	1.5B	1.4B	1.4B	1.4B	1.4B	1.4B	1.2B	1.2B	1.1B	920.3M	733.9M	672.8M	666.7M	437.2M
Retained Earnings	-2B	-2B	-1.8B	-1.6B	-1.5B	-1.4B	-1.3B	-1.5B	-1.4B	-1.3B	-1.1B	-1.1B	-1B	-899.8M	-789.6M	-673.4M	-570.2M	-487.4M	-410.5M	-351.7M
Accumulated Other Comprehensive Income/Loss	30K	119K	31K	-428K	-10K	-6K	84K	-12K	-222K	-195K	-219K	-63K	2K	23K	21K	5K	-75.8M	0.0	-4K	-16K
Total Stockholders' Equity	107.5M	146M	93.1M	117.1M	113.6M	156.4M	117.1M	-1.5B	52.1M	157.4M	285.9M	284M	-1B	266.7M	297.6M	247M	163.8M	185.6M	256.3M	85.5M
Total Equity	107.5M	146M	93.1M	117.1M	113.6M	156.4M	117.1M	-1.5B	52.1M	157.4M	285.9M	284M	-1B	266.7M	297.6M	247M	163.5M	195.8M	286.6M	85.5M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-290K	10.2M	30.3M	0.0
SUMMARY
Total Liabilities & Equity	185M	298.4M	229.4M	194.3M	136.9M	203.8M	417.7M	-1.2B	436.5M	475.6M	654.8M	471.4M	-900M	371.8M	430.5M	366.9M	257.8M	261.5M	369.3M	190.3M
Total Investments	61.9M	171.3M	147.6M	92M	22.7M	26M	235.5M	-4.5M	-4.9M	-468.4M	-413.6M	0.0	0.0	0.0	95.4M	163.9M	62M	72.9M	235.8M	49.8M
Total Debt	62.2M	108.4M	106.1M	55.3M	2.3M	12.8M	246.8M	245M	245.7M	101.4M	105.8M	107.7M	21.9M	23.5M	24.9M	28.5M	67M	30.5M	31.4M	32.2M
Net Debt	27.9M	41.7M	83.6M	8.9M	-61.8M	-113.5M	210.7M	85M	-65.1M	-245.1M	-415.5M	-231.7M	-107.3M	-199.8M	-161.4M	-18.7M	-33.6M	-55.4M	8.4M	2M
Shares Outstanding	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860	363,398,860

SEC Filings

LXRX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 16, 2026	March 16, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 02, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 29, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 06, 2025	2025	View Filing

Showing 1 to 10 of 421 filings

Related Guides

Blog Categories

Continue your LXRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.